Clostridium difficile Infection in the Intensive Care Unit

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 727-743

  Riddle, David J ^a   Dubberke, Erik R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Critical care; Intensive care; Nosocomial infection; Pseudomembranous colitis

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLESTIPOL; COLESTYRAMINE; FUSIDIC ACID; GATIFLOXACIN; IMMUNOGLOBULIN; METRONIDAZOLE; MOXIFLOXACIN; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TIACUMICIN B; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CRITICALLY ILL PATIENT; DIAGNOSTIC VALUE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERABILITY; ENTERIC FEEDING; HAND WASHING; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; NONHUMAN; PATHOGENESIS; RELAPSE; REVIEW; RISK FACTOR; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; METRONIDAZOLE; VANCOMYCIN;

EID: 68249091971     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.011     Document Type: Review

References (140)

1. Kelly T.W., Patrick M.R., and Hillman K.M. Study of diarrhea in critically ill patients. Crit Care Med 11 (1983) 7-9
2. Thakkar K., Kien C.L., Rosenblatt J.I., et al. Diarrhea in severely burned children. JPEN J Parenter Enteral Nutr 29 (2005) 8-11
3. Ringel A.F., Jameson G.L., and Foster E.S. Diarrhea in the intensive care patient. Crit Care Clin 11 (1995) 465-477
4. Liolios A., Oropello J.M., and Benjamin E. Gastrointestinal complications in the intensive care unit. Clin Chest Med 20 (1999) 329-345 viii
5. Wiesen P., Van Gossum A., and Preiser J.C. Diarrhoea in the critically ill. Curr Opin Crit Care 12 (2006) 149-154
6. Hall I.C., and O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49 (1935) 390-402
7. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 (1978) 531-534
8. Barbut F., Corthier G., Charpak Y., et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med 156 (1996) 1449-1454
9. Zilberberg M.D. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis 15 (2009) 122-124
10. Labbe A.C., Poirier L., Maccannell D., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52 (2008) 3180-3187
11. Pothoulakis C., Sullivan R., Melnick D.A., et al. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest 81 (1988) 1741-1745
12. Triadafilopoulos G., Pothoulakis C., O'Brien M.J., et al. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93 (1987) 273-279
13. Riegler M., Sedivy R., Pothoulakis C., et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95 (1995) 2004-2011
14. Voth D.E., and Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18 (2005) 247-263
15. Meyer G.K., Neetz A., Brandes G., et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun 75 (2007) 3868-3876
16. Barbut F., and Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 7 (2001) 405-410
17. Riggs M.M., Sethi A.K., Zabarsky T.F., et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45 (2007) 992-998
18. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
19. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166 (1992) 561-567
20. Dubberke E.R., Reske K.A., Olsen M.A., et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch Intern Med 167 (2007) 1092-1097
21. Shim J.K., Johnson S., Samore M.H., et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351 (1998) 633-636
22. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397
23. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
24. Lawrence S.J., Puzniak L.A., Shadel B.N., et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 28 (2007) 123-130
25. Grundfest-Broniatowski S., Quader M., Alexander F., et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 39 (1996) 619-623
26. Kyne L., Merry C., O'Connell B., et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28 (1999) 107-113
27. Gerding D.N., Muto C.A., and Owens Jr. R.C. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46 Suppl 1 (2008) S43-S49
28. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 143 (1981) 42-50
29. Kenneally C., Rosini J.M., Skrupky L.P., et al. Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest 132 (2007) 418-424
30. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 54 (2005) 1201-1205
31. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
32. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
33. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26 (2005) 273-280
34. Pepin J., Valiquette L., and Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173 (2005) 1037-1042
35. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
36. Dubberke E.R., Reske K.A., Yan Y., et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 45 (2007) 1543-1549
37. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 40 (1998) 1-15
38. Marra A.R., Edmond M.B., Wenzel R.P., et al. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis 7 (2007) 42
39. Gurwith M.J., Rabin H.R., and Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis 135 Suppl (1977) S104-S110
40. Cunningham R., Dale B., Undy B., et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 54 (2003) 243-245
41. Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 9 (2005) 45-50
42. Jump R.L., Pultz M.J., and Donskey C.J. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?. Antimicrob Agents Chemother 51 (2007) 2883-2887
43. Thorens J., Froehlich F., Schwizer W., et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 39 (1996) 54-59
44. Bliss D.Z., Guenter P.A., and Settle R.G. Defining and reporting diarrhea in tube-fed patients-what a mess. Am J Clin Nutr 55 (1992) 753-759
45. Thurn J., Crossley K., Gerdts A., et al. Enteral hyperalimentation as a source of nosocomial infection. J Hosp Infect 15 (1990) 203-217
46. Rolfe R.D. Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infect Immun 45 (1984) 185-191
47. Bliss D.Z., Johnson S., Savik K., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129 (1998) 1012-1019
48. Asha N.J., Tompkins D., and Wilcox M.H. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 44 (2006) 2785-2791
49. Crabtree T., Aitchison D., Meyers B.F., et al. Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome. Ann Thorac Surg 83 (2007) 1396-1402
50. Kelly C.P., Pothoulakis C., and LaMont J.T. Clostridium difficile colitis. N Engl J Med 330 (1994) 257-262
51. Beaulieu M., Williamson D., Pichette G., et al. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 28 (2007) 1305-1307
52. Hurley B.W., and Nguyen C.C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 162 (2002) 2177-2184
53. Mogg G.A., Burdon D.W., and Keighley M. Oral metronidazole in Clostridium difficile colitis. Br Med J 2 (1979) 335
54. Tedesco F.J. Pseudomembranous colitis: pathogenesis and therapy. Med Clin North Am 66 (1982) 655-664
55. Triadafilopoulos G., and Hallstone A.E. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 101 (1991) 685-691
56. Peterson L.R., and Kelly P.J. The role of the clinical microbiology laboratory in the management of Clostridium difficile-associated diarrhea. Infect Dis Clin North Am 7 (1993) 277-293
57. Gelone SP, Fishman N, Gerding DN, et al: Clostridium difficile epidemiology: Results of an international web-based survey project. In SHEA '06, Chicago [abstract].
58. Musher D.M., Manhas A., Jain P., et al. Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J Clin Microbiol 45 (2007) 2737-2739
59. Wilkins T.D., and Lyerly D.M. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 41 (2003) 531-534
60. Sheth S.G., and LaMont J.T. Gastrointestinal problems in the chronically critically ill patient. Clin Chest Med 22 (2001) 135-147
61. Wanahita A., Goldsmith E.A., Marino B.J., et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 115 (2003) 543-546
62. Grossmann E.M., Longo W.E., Kaminski D.L., et al. Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes. J Surg Res 88 (2000) 165-172
63. Lamontagne F., Labbe A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245 (2007) 267-272
64. Peled N., Pitlik S., Samra Z., et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol 28 (2007) 377-381
65. Wanahita A., Goldsmith E.A., and Musher D.M. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 34 (2002) 1585-1592
66. Adams S.D., and Mercer D.W. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 13 (2007) 450-455
67. Mylonakis E., Ryan E.T., and Calderwood S.B. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 161 (2001) 525-533
68. Tedesco F.J., Corless J.K., and Brownstein R.E. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 83 (1982) 1259-1260
69. Kirkpatrick I.D., and Greenberg H.M. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy. AJR Am J Roentgenol 176 (2001) 635-639
70. Kunimoto D., and Thomson A.B. Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Digestion 33 (1986) 225-228
71. Ash L., Baker M.E., O'Malley Jr. C.M., et al. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol 186 (2006) 1393-1400
72. Boland G.W., Lee M.J., Cats A.M., et al. Clostridium difficile colitis: correlation of CT findings with severity of clinical disease. Clin Radiol 50 (1995) 153-156
73. Cohen SH, Gerding DN, Johnson S, et al. Clostridium difficile infection: clinical practice guidelines by SHEA and IDSA.Oral Presentation in IDSA 45th Annual Meeting, San Diego, California.
74. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
75. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 6 Suppl 1 (1984) S235-S241
76. Olson M.M., Shanholtzer C.J., Lee Jr. J.T., et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 15 (1994) 371-381
77. Miller M.A. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 45 Suppl 2 (2007) S122-S128
78. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172
79. Friedenberg F., Fernandez A., Kaul V., et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 44 (2001) 1176-1180
80. Johnson S., Peterson L.R., and Gerding D.N. Intravenous metronidazole and Clostridium difficile-associated diarrhea or colitis. J Infect Dis 160 (1989) 1087-1088
81. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2 (1983) 1043-1046
82. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22 (1996) 813-818
83. Al-Nassir W.N., Sethi A.K., Li Y., et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52 (2008) 2403-2406
84. Salgado C.D., Giannetta E.T., and Farr B.M. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile. Infect Control Hosp Epidemiol 25 (2004) 413-417
85. Wong S.S., Woo P.C., Luk W.K., et al. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34 (1999) 1-6
86. Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamar, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). In 47th Annual ICAAC, Chicago [abstract].
87. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 (2005) 1586-1590
88. Apisarnthanarak A., Razavi B., and Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35 (2002) 690-696
89. Malnick S.D., and Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 36 (2002) 1767-1775
90. Nathanson D.R., Sheahan M., Chao L., et al. Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis Colon Rectum 44 (2001) 1871-1872
91. Rubin M.S., Bodenstein L.E., and Kent K.C. Severe Clostridium difficile colitis. Dis Colon Rectum 38 (1995) 350-354
92. Ali S.O., Welch J.P., and Dring R.J. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 74 (2008) 20-26
93. Byrn J.C., Maun D.C., Gingold D.S., et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 143 (2008) 150-154 [discussion: 155]
94. Musher D.M., Logan N., Hamill R.J., et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 43 (2006) 421-427
95. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 3 (2007) CD004610
96. Wullt M., and Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 54 (2004) 211-216
97. de Lalla F., Nicolin R., Rinaldi E., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 36 (1992) 2192-2196
98. Lagrotteria D., Holmes S., Smieja M., et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 547-552
99. Louie T., Miller M., Donskey C., et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 53 (2009) 223-228
100. Louie T.J., Emery J., Krulicki W., et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53 (2009) 261-263
101. Ng S.C., Hart A.L., Kamm M.A., et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2 (2009) 300-310
102. Lawrence S.J., Korzenik J.R., and Mundy L.M. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 54 (2005) 905-906
103. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
104. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000) 1012-1017
105. Wullt M., Hagslatt M.L., and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35 (2003) 365-367
106. Lherm T., Monet C., Nougiere B., et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 28 (2002) 797-801
107. Cassone M., Serra P., Mondello F., et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 41 (2003) 5340-5343
108. Ariano R.E., Zhanel G.G., and Harding G.K. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. CMAJ 142 (1990) 1049-1051
109. Taylor N.S., and Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141 (1980) 92-97
110. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 (1997) 366-370
111. Hassoun A., and Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother 5 (2007) 48-51
112. McPherson S., Rees C.J., Ellis R., et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49 (2006) 640-645
113. Warny M., Denie C., Delmee M., et al. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 50 (1995) 36-39
114. Juang P., Skledar S.J., Zgheib N.K., et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control 35 (2007) 131-137
115. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346 (2002) 334-339
116. Fekety R., and Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269 (1993) 71-75
117. Fernandez A., Anand G., and Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 38 (2004) 414-418
118. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 93 (1998) 1873-1876
119. Sanchez J.L., Gerding D.N., Olson M.M., et al. Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C. difficile-associated disease treatment failures and successes. Anaerobe 5 (1999) 201-204
120. Fekety R., McFarland L.V., Surawicz C.M., et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 24 (1997) 324-333
121. McFarland L.V. Alternative treatments for Clostridium difficile disease: What really works?. J Med Microbiol 54 (2005) 101-111
122. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38 (2000) 2386-2388
123. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
124. Tedesco F.J., Gordon D., and Fortson W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80 (1985) 867-868
125. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 (2007) 846-848
126. Garey K.W., Salazar M., Shah D., et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 42 (2008) 827-835
127. Boyce J.M., Ligi C., Kohan C., et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol 27 (2006) 479-483
128. Johnson S., Gerding D.N., Olson M.M., et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 88 (1990) 137-140
129. Zafar A.B., Gaydos L.A., Furlong W.B., et al. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 26 (1998) 588-593
130. Muto C.A., Blank M.K., Marsh J.W., et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 45 (2007) 1266-1273
131. Gerding D.N., Johnson S., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16 (1995) 459-477
132. Kaatz G.W., Gitlin S.D., Schaberg D.R., et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 127 (1988) 1289-1294
133. Wilcox M.H., Fawley W.N., Wigglesworth N., et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 54 (2003) 109-114
134. Perez J., Springthorpe V.S., and Sattar S.A. Activity of selected oxidizing microbicides against the spores of Clostridium difficile: relevance to environmental control. Am J Infect Control 33 (2005) 320-325
135. Valiquette L., Cossette B., Garant M.P., et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 45 Suppl 2 (2007) S112-S121
136. Fowler S., Webber A., Cooper B.S., et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 59 (2007) 990-995
137. Climo M.W., Israel D.S., Wong E.S., et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 128 (1998) 989-995
138. Davey P., Brown E., Fenelon L., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 4 (2005) CD003543
139. Khan R., and Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 54 (2003) 104-108
140. O'Connor K.A., Kingston M., O'Donovan M., et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 97 (2004) 423-429